Immatics (IMTX) Cash from Investing Activities (2019 - 2025)
Immatics recorded quarterly Cash from Investing Activities of -$33.7 million in Q4 2025, down 123.48% quarter-over-quarter from $143.4 million in Q3 2025, and up 33.55% year-over-year from -$25.2 million in Q4 2024.
Immatics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$33.7 million for Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 33.55% year-over-year to -$33.7 million; the TTM figure through Dec 2025 stood at $231.7 million (up 240.78% YoY), while the FY2025 annual figure was $231.4 million, up 242.08% from the prior year.
- Cash from Investing Activities came in at -$33.7 million for Q4 2025 at Immatics, down from $143.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $143.4 million in Q3 2025 to a low of -$262.7 million in Q1 2024.
- A 5-year average of -$8.7 million and a median of -$3.0 million in 2023 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 510.15% in 2024 and fell as far as 6481.11% in 2024.
- Immatics' Cash from Investing Activities stood at -$2.1 million in 2021, then tumbled by 4300.84% to -$92.0 million in 2022, then soared by 169.84% to $64.3 million in 2023, then tumbled by 178.82% to -$50.7 million in 2024, then soared by 33.55% to -$33.7 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$33.7 million, $143.4 million, and $72.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -33.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33.66 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Sep 30, 2023 | -76.82 Mn |
| Sep 30, 2023 | -76.82 Mn |
| Jun 30, 2023 | -18.33 Mn |
| Jun 30, 2023 | -18.33 Mn |
| Mar 31, 2023 | -3.99 Mn |
| Mar 31, 2023 | -3.99 Mn |
| Dec 31, 2022 | -92.03 Mn |
| Dec 31, 2022 | -92.03 Mn |
| Sep 30, 2022 | -71.65 Mn |
| Sep 30, 2022 | -71.65 Mn |
| Jun 30, 2022 | -58.01 Mn |
| Jun 30, 2022 | -58.01 Mn |
| Mar 31, 2022 | 6.55 Mn |
| Mar 31, 2022 | 6.55 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Sep 30, 2021 | 23.15 Mn |
| Sep 30, 2021 | 23.15 Mn |
| Jun 30, 2021 | -15.49 Mn |
| Jun 30, 2021 | -15.49 Mn |
| Mar 31, 2021 | 3.09 Mn |
| Mar 31, 2021 | 3.09 Mn |
| Dec 31, 2020 | -474,531.36 |
| Dec 31, 2020 | -474,531.36 |
| Sep 30, 2020 | -31.56 Mn |
| Sep 30, 2020 | -31.56 Mn |
| Jun 30, 2020 | 33.81 Mn |
| Jun 30, 2020 | 33.81 Mn |
| Mar 31, 2020 | -21.22 Mn |
| Mar 31, 2020 | -21.22 Mn |
| Dec 31, 2019 | -18.59 Mn |
| Dec 31, 2019 | -18.59 Mn |
| Sep 30, 2019 | 14.30 Mn |
| Sep 30, 2019 | 14.30 Mn |